Abstracts Archive - Page 799 of 2607 - ACR Meeting Abstracts

Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Jesús T. Sánchez-Costa¹, Iñigo Hernández-Rodríguez², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Jesús A. Valero-Jaimes⁵, Ismael González-Fernández⁶, Julio Sánchez⁷, Judit Lluch⁸, Eva Galindez-Agirregoikoa⁹, Javier Mendizábal-Mateos¹⁰, Pia M. Lois Bermejo¹¹, Javier Loricera¹², Alejandro Muñoz¹³, Cristina Valero-Martínez¹⁴, Patricia Moya¹⁵, Carmen Larena-Grijalba¹⁶, Vanessa A. Navarro-Angeles¹⁷, Joan Calvet-Fontova¹⁸, Ivette Casafont¹⁹, Francisco Ortiz-Sanjuán²⁰, Selene Labrada-Arrabal²¹, Jaime Calvo-Alén²², Carlota L. Iñiguez-Ubiaga²³, Vanesa Hernández²⁴, Cristina Campos-Fernández²⁵, María Alcalde-Villar²⁶, Antonio Juan-Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal³¹, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³², ¹Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰H. Navarra, Navarra, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁴Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁰H. La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…
Abstract Number: 1409 • ACR Convergence 2021
Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
Francesca Regola¹, Giovanni Bosio², Laura Andreoli³, Franco Franceschini¹ and Paola Toniati¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, ³University of Brescia, Brescia, Italy
Background/Purpose: Giant Cell Arteritis (GCA) is the most frequent systemic vasculitis in patients older than 50 years involving medium-sized and large arteries. Inflammation of the…
Abstract Number: 1410 • ACR Convergence 2021
Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
Kathleena D'Anna¹, David Lim², Lorena Salto¹ and Mehrnaz Hojjati¹, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University Health, Redlands, CA
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
Abstract Number: 1411 • ACR Convergence 2021
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
Fernando Montero¹, Juan Molina², ISABEL CASTREJON³, Julia Martínez Barrio¹, Juan Carlos Nieto¹ and Jose Maria Alvaro-Gracia¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Maran, Madrid, Spain, ³Pfizer Spain, Chicago
Background/Purpose: The implementation of ultrasound (US) fast-track pathways (FTP), aiming at an early diagnosis of giant cell arteritis (GCA), has led to a decrease in…
Abstract Number: 1412 • ACR Convergence 2021
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Lara Sánchez-Bilbao¹, Javier Loricera¹, Juan Pablo Valdivieso Achá², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Valvanera Pinillos²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario La Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Ramón y Cajal, Madrid. Spain., Madrid, Spain, ²⁷Hospital San Pedro, Logroño, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…
Abstract Number: 1413 • ACR Convergence 2021
Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis
Mark Matza¹, Adam Jarvie², Ana Fernandes¹, John Stone³ and Sebastian Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Masssachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Winchester, MA
Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis…
Abstract Number: 1414 • ACR Convergence 2021
The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States
Mark Matza¹, Karina Torralba² and Minna Kohler³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
Abstract Number: 1415 • ACR Convergence 2021
Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence
Christopher McMaster¹, Victor Yang¹, Benjamin Sutu², Shereen Oon³, Gene-Siew Ngian³, Ian Wicks³, Russell Buchanan⁴ and David Liew¹, ¹Austin Health, Heidelberg, Australia, ²Melbourne Health, South Yarra, Australia, ³Melbourne Health, Parkville, Australia, ⁴Austin Health, Heidelberg, Melbourne, Australia
Background/Purpose: Studies of giant cell arteritis (GCA) rely on classifying temporal artery biopsies (TABs), the gold-standard diagnostic test. However, these results exist as free text,…
Abstract Number: 1416 • ACR Convergence 2021
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
Idil Esen¹, Philip Therkildsen², Berit Dalsgaard Nielsen², Anna van 't Ende¹, Annemieke Boots¹, Peter Heeringa¹, Ellen-Margrethe Hauge², Elisabeth Brouwer¹ and Yannick van Sleen³, ¹University Medical Center Groningen, Groningen, Netherlands, ²Aarhus University Hospital, Aarhus, Denmark, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
Abstract Number: 1417 • ACR Convergence 2021
Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors
Christopher McMaster¹, Victor Yang¹, Russell Buchanan² and David Liew¹, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Heidelberg, Melbourne, Australia
Background/Purpose: To determine whether an eventual diagnosis of giant cell arteritis in both temporal artery biopsy positive and negative patients can be identified using prospective…
Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen¹, Kornelis van der Geest², Annemieke Boots², Maria Sandovici² and Elisabeth Brouwer², ¹University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…
Abstract Number: 1419 • ACR Convergence 2021
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Mwidimi Ndosi¹, Celia Almeida², Jill Dawson³, Emma Dures², Rosemary Greenwood⁴, Catherine Guly⁵, Sarah Mackie⁶, Alison Bromhead⁴, Steve Stern⁴ and Joanna Robson², ¹University of the West of England, Bristol, Filton, United Kingdom, ²UWE Bristol, Bristol, United Kingdom, ³University of Oxford, Oxford, ⁴University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, ⁶School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 1421 • ACR Convergence 2021
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Renaud Felten¹, Lou KAWKA², Maxime DUBOIS², Manuel Ugarte-Gil³, Yurilis Fuentes-Silva⁴, Matteo PIGA⁵ and Laurent Arnaud¹, ¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ²National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ³Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy
Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic…
Abstract Number: 1422 • ACR Convergence 2021
Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Derek Fine¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: Diagnosis of lupus nephritis (LN) relies on a kidney biopsy obtained in SLE with proteinuria. Delayed access to kidney biopsies may delay diagnosis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].